Day: June 14, 2024

Updated analyses of data from AURORA and BEACON studies further demonstrate clinical activity of bitopertin across multiple measures of erythropoietic protoporphyria (EPP) and support development path forward Additional data from the ongoing Phase 1b trial of DISC-0974 in myelofibrosis (MF) patients continued to demonstrate greater than 60% hematologic response rates, with durable increases in hemoglobin levels and reductions in transfusion burden Positive data from initial single-ascending dose (SAD) cohorts of a Phase 1 trial of DISC-3405 in healthy volunteers demonstrated sustained, meaningful induction of hepcidin and >50% suppression of mean serum ironWATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and...

Toronto, ON, June 14, 2024 (GLOBE NEWSWIRE) — Plato Gold Corp. (TSX-V: PGC) (OTCQB: NIOVF) (Frankfurt: 4Y7 or WKN: A0M2QX) (“Plato” or the “Company“) an exploration company with a portfolio of properties in Northern Ontario and Santa Cruz, Argentina is pleased to welcome Mr. Ernie J. Marcotte as the newest member of our Board of Directors. “On behalf of our Board, I am very pleased to welcome Mr. Ernie Marcotte as a new Director. I look forward to working with Ernie who brings a wealth of experience and expertise in the mining sector. Ernie will be joining our seasoned team of professionals, each with a proven record of success in the mining industry or related business sector,” said Anthony Cohen, President and CEO. “I am pleased to serve as a director for Plato Gold and look forward to...

SINGAPORE, June 14, 2024 (GLOBE NEWSWIRE) — JOYY Inc. (Nasdaq: YY) (“JOYY” or the “Company”), a global technology company, today announced the results of its previously announced repurchase right offer relating to its 1.375% Convertible Senior Notes due 2026 (CUSIP No. 98426T AF3) (the “2026 Notes”). The repurchase right offer expired at 5:00 p.m., New York City time, on Thursday, June 13, 2024. Based on information from Citibank, N.A. as the paying agent for the 2026 Notes, US$405,445,000 aggregate principal amount of the 2026 Notes were validly surrendered and not withdrawn prior to the expiration of the repurchase right offer. The aggregate cash purchase price of these 2026 Notes is US$405,445,000. The Company has accepted all of the surrendered 2026 Notes for repurchase and has forwarded cash in payment of the same to the paying...

Patients treated with 100 mg bezuclastinib showed substantial reduction in their most severe symptoms and mast cell reactions Reductions were shown in all individual MS2D2 symptoms across domains and objective reduction in skin lesions corresponding with symptomatic improvement WALTHAM, Mass. and BOULDER, Colo., June 14, 2024 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced additional data from Part 1 of its ongoing SUMMIT clinical trial evaluating the selective KIT D816V inhibitor, bezuclastinib, in patients with nonadvanced systemic mastocytosis (NonAdvSM). The data are being presented today in a poster presentation at the 2024 European Hematology Association (EHA) Congress taking place in Madrid, Spain. “We...

AB “KN Energies” (hereinafter – the Company or KN) informs that the Company’s Supervisory Council adopted the following decisions regarding the submission of the opinion and proposals to the Company’s Extraordinary General Meeting of Shareholders. The Company’s Supervisory Council submits proposals to the Extraordinary General Meeting of Company’s Shareholders to be held on 27 June 2024: “AB “KN Energies” Supervisory Council, in accordance with Article 32, Part 1, Point 10 of the Law on Companies of the Republic of Lithuania, and taking into account:the recommendation to the Board, submitted on May 30, 2024 by the Company’s Remuneration and Nomination Committee, to agree the amendment of the Remuneration Policy of AB “KN Energies” and submit it for the approval at the General Meeting of Shareholders of AB “KN...

Pseudovirus in vitro neutralization data show continued neutralizing activity of VYD222 (pemivibart) against the KP.1.1 FLiRT and KP.3 SARS-CoV-2 variants, virus selections representative of current dominant strains and the most recent FLiRT-containing viruses Invivyd’s new data is broadly concordant with preliminary pseudovirus data showing neutralizing activity of VYD222 against KP.2 FLiRT and KP.3 variants recently publicized by an independent academic lab Invivyd’s next anticipated SARS-CoV-2 monoclonal antibody (mAb) candidate, VYD2311, also shows continued in vitro neutralization activity in pseudovirus assays against these predominant strains to dateWALTHAM, Mass., June 14, 2024 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious...

SUNNYVALE, Calif., June 14, 2024 (GLOBE NEWSWIRE) — eGain (NASDAQ: EGAN), the leading AI knowledge platform for customer service, today announced that Virginia529 has selected the eGain Knowledge Hub™ to enhance its customer service. Virginia529 strives to help make the financial lives of Virginians—and all Americans—better through its commitment to affordable and accessible savings programs and financial education. Available nationwide with account owners in every state, Virginia529 is the largest 529 plan, managing more than $100 billion in assets, as of February 29, 2024. In addition to being the industry leader for higher education savings, Virginia529 also administers a disability savings program (ABLEnow) and manages a state-facilitated retirement savings program (RetirePath Virginia). Virginia529’s leadership constantly...

14 June 2024 LEI: 2138003QW2ZAYZODBU23 LSE Code: 3SIS WISDOMTREE MULTI ASSET ISSUER PUBLIC LIMITED COMPANY(a public company incorporated with limited liability in Ireland)WISDOMTREE SILVER 3X DAILY SHORT SECURITIES ISIN: IE00B8JG1787 PROPOSED AMENDMENT TO THE PRINCIPAL AMOUNT OF THE AFFECTED SECURITIES ADJOURNMENT OF MEETING OF THE ETP SECURITYHOLDERS THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about what action you should take, you are recommended to consult your independent financial adviser. If you have sold or transferred all of your WisdomTree Silver 3x Daily Short Securities (the “Affected Securities”) of WisdomTree Multi Asset Issuer Public Limited Company (the “Issuer”), please send this document, together with the accompanying form of proxy, at once to the purchaser or transferee or...

Date: Friday, August 2, 2024 Time: 10:00 a.m. (Eastern Time) BROOKFIELD NEWS, June 14, 2024 (GLOBE NEWSWIRE) — You are invited to participate in Brookfield Business Partners’ 2024 Second Quarter Conference Call & Webcast on Friday, August 2, 2024 at 10:00 a.m. (Eastern Time) to discuss with members of senior management our results and current business initiatives. Results will be released on Friday, August 2, 2024 prior to 8:00 a.m. (Eastern Time) and will be available following the release on our website at https://bbu.brookfield.com. Participants can join by conference call or webcast: Conference CallPlease pre-register: BBU2024Q2ConferenceCall Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. This process will bypass the operator and avoid the queue.WebcastPlease join and register...